Kreztel-H 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion, which leads to vasodilation and reduction in blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, resulting in decreased plasma volume and peripheral resistance. The synergistic action of these two agents effectively lowers elevated blood pressure in patients with essential hypertension, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Kreztel-H 40 is indicated for patients inadequately controlled on monotherapy or those who require combination therapy for optimal blood pressure management. It is important to monitor renal function, electrolytes, and blood pressure regularly during treatment. Caution is advised in patients with renal or hepatic impairment, electrolyte imbalances, or a history of hypersensitivity to sulfonamides. Kreztel-H 40 should be used under medical supervision, with adherence to prescribed dosing to achieve desired therapeutic outcomes while minimizing adverse effects.